Theorem teams with Charles River on preclinical work

Theorem Clinical Research has struck a deal with Charles River Laboratories ($CRL), adding the early-phase-focused CRO's capabilities to its drug development platform.

Under the agreement, Charles River will provide bioanalysis, immunogenicity and immunology testing to support Theorem's clinical trials, offering clients an end-to-end platform for drug development, Theorem said.

Charles River's early-phase heft includes a wealth of animal models, state-of-the-art preclinical testing technology and a bioanalysis portfolio, making it a go-to partner for CROs in need of preclinical work, Executive Director Alan Bartlett said. Now, teaming up with Theorem, Charles River has found a new client base for its services.

"Sponsors will benefit from the experience of both organizations," Bartlett said in a statement. "The alliance will offer a seamless transition from preclinical testing into the clinical arena."

Like many early-stage CROs, Charles River is facing a decline in demand for discovery services, but the Wilmington, MA, researcher has managed to grow in a stilted market, last quarter seeing sales climb 2.9% to $292.9 million.

- read the announcement

Special Report: How can early-phase CROs stay afloat in a changing market?